United Therapeutics had a robust start to 2024, with total revenue increasing 34% to $677 million. Strong demand for Tyvaso DPI, a dry-powder inhaler for the treatment of pulmonary arterial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback